Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc. has demonstrated significant revenue growth, with FY24 net product revenues surging by 140% to $607.6 thousand and a notable increase of 223% year-over-year in Q3 FY25 net product revenue to $438 thousand. The continuous rise in ARAKODA deliveries highlights the product's strong market uptake, suggesting substantial growth potential as sales rose to 1,505 boxes in Q3 FY25 compared to 1,319 boxes a year prior. Additionally, the favorable safety profile of tafenoquine opens up opportunities for combination therapies, which could further enhance its market applicability and revenue avenues moving forward.

Bears say

60 Degrees Pharmaceuticals Inc has experienced a reduction in product revenues to $100,000 due to supply constraints, raising concerns about the company’s revenue ramp visibility. The firm reported a gross loss of approximately $9,000, a stark contrast to the gross profit of $36,000 in the previous quarter, primarily due to a one-time inventory write-off. Furthermore, uncertainties surrounding regulatory approvals for new indications and the risk of dilution from potential financing pose significant challenges to investor confidence and the company’s financial outlook.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.